This study examined the relationship between blood-brain-barrier permeability (BBBp), measured by cerebrospinal fluid/serum albumin ratio (QAlb), and cognitive decline progression in a clinical cohort.
This prospective observational study included 334 participants from the BIODEGMAR cohort. Cognitive decline progression was defined as an increase in Global Deterioration Scale and/or Clinical Dementia Rating scores. Associations between BBBp, demographics, and clinical factors were explored.
Male sex, diabetes mellitus, and cerebrovascular burden were associated with increased log-QAlb. Vascular cognitive impairment patients had the highest log-QAlb levels. Among the 273 participants with valid follow-up data, 154 (56.4%) showed cognitive decline progression. An 8% increase in the hazard of clinical worsening was observed for each 10% increase in log-QAlb.
These results suggest that increased BBBp in individuals with cognitive decline may contribute to clinical worsening, pointing to potential targeted therapies. QAlb could be a useful biomarker for identifying patients with a worse prognosis.

If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.

This post is Copyright: Albert Puig‐Pijoan,
Joan Jimenez‐Balado,
Aida Fernández‐Lebrero,
Greta García‐Escobar,
Irene Navalpotro‐Gómez,
Jose Contador,
Rosa‐María Manero‐Borràs,
Victor Puente‐Periz,
Antoni Suárez,
Francisco J. Muñoz,
Oriol Grau‐Rivera,
Marc Suárez‐Calvet,
Rafael Torre,
Jaume Roquer,
Angel Ois | September 20, 2023

Wiley: Alzheimer’s & Dementia: Table of Contents